ASND as reported
Ascendis Pharma A/S reported €720M of revenue over the trailing twelve months, +98% on the year before. 10 reported series are charted on this page, each one as filed.
€720M
Revenue, trailing twelve months · to Q4 2025 · +98% against the twelve months before
- Net Income
- −€228M
Net Income · −40% year on year · trailing twelve months to Q4 2025
- Op Margin
- −32%
Op Margin · trailing twelve months to Q4 2025
- EPS
- −€3.83
EPS · trailing twelve months to Q3 2025
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | €720M | +98% | Q4 2025 |
| Net Income | −€228M | −40% | Q4 2025 |
| EPS | −€3.83 | n/a | Q3 2025 |
| Gross Margin | 86% | n/a | Q4 2025 |
| Op Margin | −32% | n/a | Q4 2025 |
| Net Margin | −40% | n/a | Q4 2025 |
| ROE | 150% | n/a | Q4 2025 |
| ROA | −24% | n/a | Q4 2025 |
| ROIC | −282% | n/a | Q4 2025 |
| Free Cash Flow | −€308M | n/a | Q4 2024 · 4 quarters behind |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Ascendis Pharma A/S (ASND) - Revenue & ProfitRevenue & ProfitAscendis Pharma A/S (ASND)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Biotechnology
Ranks #59 of 145 by Smart Score